You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm wants to develop a test that can provide objective, reliable, and rapid information so that clinicians can make critical decisions in circumstances of high uncertainty.
The initiative may lead to a test that enables clinicians to determine the presence of bacterial infections within 10 minutes.
The ASPIRE algorithm uses cell phenotype information from bone marrow samples to predict which patients will relapse and which will go into remission.
The test may mitigate potential interference during immunofixation tests that measure a patient’s response to a multiple myeloma therapy.
UCSF said that the healthcare computing platform will use deep learning to analyze EHR, omics, wearables, and IoT sensor data.
The firm is developing an electrochemical sensor platform to detect sepsis and other conditions using a single drop of blood and a single-use cartridge.
Stanford researchers showed that wearables could identify inflammation, insulin resistance, and the onset of infection.
The firm said that it will manufacture assays for its next-generation immunoassay and clinical chemistry system at an expanded facility.
T2 said it's in a strong position to achieve planned portfolio milestones over the next two years, including submitting its next test for FDA clearance next year.
The test is based on a biomarker signature that consists of a core set of 31 genes associated with endotoxin tolerance in sepsis patients.